Related Experiment Video
Updated: Oct 10, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Outcome observability in evidence on proton pump inhibitor-associated clostridioides difficile outcomes: a
1Department of Pathophysiology, College of Basic Medical Science, Clinical Medical College of Anhui Medical University, Hefei, China.
Objectives:
Evidence on proton pump inhibitor (PPI) exposure and Clostridioides difficile infection (CDI) remains difficult to interpret because published estimates arise from heterogeneous target outcomes, risk sets, exposure contrasts, time structures, and ascertainment procedures. We evaluated whether a result-specific outcome-observability framework could make these differences explicit without using effect direction or statistical significance as classification criteria.
Study Design And Setting:
We conducted a structured methodological audit of evidence sources evaluating PPI exposure and CDI-related outcomes. Original observational reports and observational or randomized trial-based meta-analytic reports were retained as distinct evidence types.
Methods:
For each eligible reported result, we extracted the target outcome and risk set, PPI exposure contrast, time zero and exposure/outcome windows, outcome ascertainment, effect measure, event information, and data-source dependence. Four observability domains were coded as explicit/target-aligned (E), partial/proxy-based (P), unclear/misaligned (U), or aggregate/mixed (A). Codes were not summed, weighted, or dichotomized. Meta-analytic reports were described as aggregate evidence, and odds ratios, risk ratios, and hazard ratios were not treated as quantitatively interchangeable.
Results:
Eleven evidence sources contained an eligible PPI exposure contrast for a CDI-related outcome after one report was excluded during result-level reassessment. Eight addressed incident CDI, one addressed C. difficile detection without uniform confirmation of clinical CDI, one addressed severity among patients with established CDI, and one addressed mortality among patients with established CDI. Nine estimates were odds ratios, one was a risk ratio, and one was a hazard ratio. Temporal alignment and outcome ascertainment varied across original reports, while three meta-analytic reports combined heterogeneous component definitions. Two Swedish registry reports were treated as one overlapping data-source cluster.
Conclusions:
The included estimates did not represent one common PPI-CDI estimand. A result-specific outcome-observability profile can identify methodological non-comparability, but it is not a score of study quality, causal validity, statistical power, or likelihood of a positive result. The framework should be interpreted as a descriptive methodological audit rather than evidence that observability conditions explain the direction of reported associations.
Related Concept Videos
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care evaluation by...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Investigation of Disease Outbreaks
Clinical Significance of Antibiotic Resistance
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...